Visceral Adiposity Index is a predictor of incident colorectal cancer: a population-based longitudinal study
- PMID: 32595114
- PMCID: PMC7322272
- DOI: 10.1136/bmjgast-2020-000400
Visceral Adiposity Index is a predictor of incident colorectal cancer: a population-based longitudinal study
Abstract
Objective: The Visceral Adiposity Index (VAI) is a marker of visceral fat accumulation and dysfunction. We aimed to investigate the association between VAI and incident colorectal cancer (CRC).
Design: In this historical cohort study of 27 921 (16 434 men and 11 487 women) participants, we divided the participants into tertiles according to VAI. We calculated VAI: men, VAI = (waist circumference (WC)/(39.68+1.88 × body mass index (BMI))) × (triglycerides (TG)/1.03) × (1.31/high-density lipoprotein cholesterol (HDL)); women, VAI = (WC/(36.58+1.89 × BMI)) × (TG/0.81) × (1.52/HDL). We performed Cox proportional hazard models, adjusting for sex, age, smoking, alcohol consumption, exercise, haemoglobin A1c and systolic blood pressure.
Results: During the median 4.4-year follow-up, 116 participants developed CRC. Compared with the lowest tertile, the HRs of incident CRC in the middle and the highest tertiles were 1.30 (95% CI 0.76 to 2.28, p=0.338) and 2.41 (1.50 to 4.02, p<0.001) in univariate analysis. Moreover, the HRs of incident CRC in the middle and the highest tertiles were 1.27 (0.73 to 2.23, p=0.396) and 1.98 (1.15 to 3.39, p=0.013) after adjusting for covariates.
Conclusions: VAI can be a predictor of incident CRC. For early detection, we should encourage people with high VAI to undergo screening for CRC.
Keywords: colorectal cancer; epidemiology; obesity.
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: YH received grants from Asahi Kasei Corporation outside the submitted work. MF received grants from AstraZeneca, Astellas Pharma, Nippon Boehringer Ingelheim Co., Daiichi Sankyo Co., Eli Lilly Japan K.K., Kyowa Hakko Kirin Co., Kissei Pharmaceutical Co., MSD K.K., Mitsubishi Tanabe Pharma Corp., Novo Nordisk Pharma, Sanwa Kagaku Kenkyusho Co., Sanofi K.K., Ono Pharmaceutical Co., and Takeda Pharmaceutical Co., outside the submitted work. The sponsors were not involved in the study design; in the collection, analysis, interpretation of data; in the writing of this manuscript; or in the decision to submit the article for publication. The authors, their immediate families, and any research foundations with which they are affiliated have not received any financial payments or other benefits from any commercial entity related to the subject of this article. The authors declare that although they are affiliated with a department that is supported financially by pharmaceutical company, the authors received no current funding for this study, and this does not alter their adherence to all the journal policies on sharing data and materials.
Figures


Similar articles
-
The visceral adiposity index is a predictor of incident nonalcoholic fatty liver disease: A population-based longitudinal study.Clin Res Hepatol Gastroenterol. 2020 Jun;44(3):375-383. doi: 10.1016/j.clinre.2019.04.002. Epub 2020 May 17. Clin Res Hepatol Gastroenterol. 2020. PMID: 32434704
-
The Visceral Adiposity Index Is a Predictor of Incident Chronic Kidney Disease: A Population-Based Longitudinal Study.Kidney Blood Press Res. 2020;45(3):407-418. doi: 10.1159/000506461. Epub 2020 Mar 30. Kidney Blood Press Res. 2020. PMID: 32224619
-
Visceral adiposity index and longitudinal risk of incident metabolic syndrome: Korean genome and epidemiology study (KoGES).Endocr J. 2020 Jan 28;67(1):45-52. doi: 10.1507/endocrj.EJ19-0008. Epub 2019 Oct 12. Endocr J. 2020. PMID: 31611471
-
The application of visceral adiposity index in identifying type 2 diabetes risks based on a prospective cohort in China.Lipids Health Dis. 2014 Jul 8;13:108. doi: 10.1186/1476-511X-13-108. Lipids Health Dis. 2014. PMID: 25002013 Free PMC article.
-
Association Between Visceral Obesity Index and Diabetes: A Systematic Review and Meta-analysis.J Clin Endocrinol Metab. 2024 Sep 16;109(10):2692-2707. doi: 10.1210/clinem/dgae303. J Clin Endocrinol Metab. 2024. PMID: 38709677 Free PMC article.
Cited by
-
Cardio-Metabolic Indices and Metabolic Syndrome as Predictors of Clinical Severity of Gastroenteropancreatic Neuroendocrine Tumors.Front Endocrinol (Lausanne). 2021 Mar 18;12:649496. doi: 10.3389/fendo.2021.649496. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33815296 Free PMC article.
-
Implication of Obesity and Gut Microbiome Dysbiosis in the Etiology of Colorectal Cancer.Cancers (Basel). 2023 Mar 22;15(6):1913. doi: 10.3390/cancers15061913. Cancers (Basel). 2023. PMID: 36980799 Free PMC article. Review.
-
Association of novel and conventional obesity indices with colorectal cancer risk in older Chinese: a 14-year follow-up of the Guangzhou Biobank Cohort Study.BMC Cancer. 2023 Mar 29;23(1):286. doi: 10.1186/s12885-023-10762-0. BMC Cancer. 2023. PMID: 36991401 Free PMC article.
-
The association between visceral adiposity index and decreased renal function: A population-based study.Front Nutr. 2023 Mar 10;10:1076301. doi: 10.3389/fnut.2023.1076301. eCollection 2023. Front Nutr. 2023. PMID: 36969806 Free PMC article.
-
Relationship between BMI, CT-derived body composition and colorectal neoplasia in a bowel screening population.Scott Med J. 2022 Aug;67(3):93-102. doi: 10.1177/00369330221102237. Epub 2022 May 22. Scott Med J. 2022. PMID: 35603880 Free PMC article.
References
-
- World Health Organization Cancer sheets, 2018. Available: http://www.who.int/news-room/fact-sheets/detail/cancer [Accessed 20 Dec 2018].
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous